Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 2
2011 2
2012 2
2013 2
2014 2
2015 5
2016 1
2017 2
2018 5
2019 2
2020 5
2021 3
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Integrin Signaling Shaping BTK-Inhibitor Resistance.
Polcik L, Dannewitz Prosseda S, Pozzo F, Zucchetto A, Gattei V, Hartmann TN. Polcik L, et al. Among authors: hartmann tn. Cells. 2022 Jul 18;11(14):2235. doi: 10.3390/cells11142235. Cells. 2022. PMID: 35883678 Free PMC article. Review.
Rac GTPases in Hematological Malignancies.
Durand-Onaylı V, Haslauer T, Härzschel A, Hartmann TN. Durand-Onaylı V, et al. Among authors: hartmann tn. Int J Mol Sci. 2018 Dec 14;19(12):4041. doi: 10.3390/ijms19124041. Int J Mol Sci. 2018. PMID: 30558116 Free PMC article. Review.
Editorial: Metabolism and Cell Adhesion in Cancer.
Hartmann TN. Hartmann TN. Front Cell Dev Biol. 2022 Mar 3;10:871471. doi: 10.3389/fcell.2022.871471. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35309943 Free PMC article. No abstract available.
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
Alsadhan A, Chen J, Gaglione EM, Underbayev C, Tuma PL, Tian X, Freeman LA, Baskar S, Nierman P, Soto S, Itsara A, Ahn IE, Sun C, Bibikova E, Hartmann TN, Mhibik M, Wiestner A. Alsadhan A, et al. Among authors: hartmann tn. Clin Cancer Res. 2023 Sep 15;29(18):3612-3621. doi: 10.1158/1078-0432.CCR-22-3217. Clin Cancer Res. 2023. PMID: 37227160 Free PMC article.
Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma.
Evers M, Schreder M, Stühmer T, Jundt F, Ebert R, Hartmann TN, Altenbuchinger M, Rudelius M, Kuric M, Rindt WD, Steinbrunn T, Langer C, Heredia-Guerrero SC, Einsele H, Bargou RC, Rosenwald A, Leich E. Evers M, et al. Among authors: hartmann tn. Blood Cancer J. 2023 Mar 23;13(1):43. doi: 10.1038/s41408-023-00817-7. Blood Cancer J. 2023. PMID: 36959208 Free PMC article. No abstract available.
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R. Egle A, et al. Among authors: hartmann tn. Ann Hematol. 2018 Sep;97(9):1745. doi: 10.1007/s00277-018-3403-9. Ann Hematol. 2018. PMID: 29934835 Free PMC article.
39 results